Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-752 in Dengue Human Challenge Model
NCT05366439Phase 1Terminated
- Sponsor
- Atea Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dengue fever comparing AT-752 with Placebo (2 arms). Primary endpoint: Mean quantitative RNAemia (peak and duration and AUC). Started Apr 2022; status: terminated.
02
Drugs
arbemnifosbuvir
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT05366439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05366439.